$LRMR News

Wedbush Maintains Outperform on Larimar Therapeutics, Lowers Price Target to $11

Larimar Therapeutics Q2 EPS $(0.30) Beats $(0.39) Estimate

HC Wainwright & Co. Assumes Larimar Therapeutics at Buy, Announces Price Target of $10

Larimar Therapeutics, Inc. (LRMR) Discusses Regulatory Progress and Long-Term Data for Nomlabofusp in Friedreich's Ataxia - Slideshow

Baird Maintains Outperform on Larimar Therapeutics, Lowers Price Target to $5

Larimar Therapeutics, Inc. (LRMR) Discusses Regulatory Progress and Long-Term Data for Nomlabofusp in Friedreich's Ataxia Transcript

Larimar Stock Slides 15% Despite FDA Backing Rolling Submission For Rare Disease Drug

Larimar Therapeutics Submits First Module Of Rolling BLA Submission To FDA For Accelerated Approval Of Nomlabofusp; Remaining Modules Expected To Be Submitted In H2 2026

Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich’s Ataxia

JP Morgan Initiates Coverage On Larimar Therapeutics with Overweight Rating, Announces Price Target of $9

Wedbush Maintains Outperform on Larimar Therapeutics, Lowers Price Target to $12

Larimar Therapeutics Reports First Quarter 2026 Financial and Business Update

Larimar Therapeutics Q1 EPS $(0.31) Beats $(0.54) Estimate

Larimar Therapeutics Publishes Cross-Species Findings Supporting Skin as a Surrogate for the Measurement of Frataxin in Tissues Clinically Relevant to Friedreich’s Ataxia

Wedbush Raises its Price Target on Larimar Therapeutics (LRMR) to $13

Wedbush Maintains Outperform on Larimar Therapeutics, Raises Price Target to $13

Larimar: Q4 Earnings Snapshot

Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

Larimar Therapeutics Q4 EPS $(0.73) Misses $(0.45) Estimate

Larimar Therapeutics to Participate in Upcoming Investor Conferences in March